BioLineRx Ltd. Provides Clarification Regarding Interim Analysis of CLARITY Trial for BL-1020
Published: Feb 04, 2013
JERUSALEM--(BUSINESS WIRE)--BioLineRx Ltd. (NASDAQ: BLRX)(TASE: BLRX), a biopharmaceutical development company, notes that, as previously disclosed, results from the interim analysis of the Phase II/III CLARITY clinical trial of BL-1020, a first in class, orally available, GABA-enhanced antipsychotic for the treatment of schizophrenia, are expected to be reported during the week of March 18, 2013. The CLARITY trial is a randomized, double-blind trial to examine acute (6 weeks) and long-term (24 weeks) cognitive and antipsychotic efficacy, safety and tolerability of BL-1020 on patients with acute schizophrenia. The interim analysis will be performed on data of approximately 235 randomized patients from 27 sites in Romania and India.